0.7585

2.71% 0.02

Pre-market: .78 0.0215 +2.83%

Atossa Therapeutics Inc (ATOS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Atossa Therapeutics Inc stock is traded at $0.7585, with a volume of 683.59K. It is up +2.71% in the last 24 hours and down -10.56% over the past month. Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Previous Close:

$0.7385

Open:

$0.7428

24h Volume:

683.59K

Relative Volume:

0.81

Market Cap:

$97.98M

Revenue:

Net Income/Loss:

$-26.91M

P/E Ratio:

-3.4477

EPS:

-0.22

Net Cash Flow:

$-19.57M

1W Performance:

-2.73%

1M Performance:

-10.56%

6M Performance:

-11.50%

1Y Performance:

-35.17%

1-Day Range:

$0.734

$0.7741

1-Week Range:

$0.6848

$0.7997

52-Week Range:

$0.5526

$1.2982

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name

Atossa Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

206.588.0256

Address

10202 5TH AVENUE NE, SEATTLE, WA

Employee

Twitter

@atossainc

Next Earnings Date

2025-03-25

Latest SEC Filings

ATOS's Discussions on Twitter

Compare ATOS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATOS Atossa Therapeutics Inc	0.7585	95.39M	0	-26.91M	-19.57M	-0.22
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-18	Initiated	Maxim Group	Buy

Atossa Therapeutics Inc Stock (ATOS) Latest News

Dec 04, 2025

Will Atossa Therapeutics Inc. stock outperform tech sector in 2025July 2025 Recap & Safe Capital Investment Plans - Newser

Dec 04, 2025

Is Atossa Therapeutics Inc. (YAG2) stock a buy before new product rolloutQuarterly Portfolio Report & Fast Momentum Entry Tips - Newser

Dec 04, 2025

Atossa Completes FDA Meeting on Regulatory Strategies - TipRanks

Dec 04, 2025

Atossa Therapeutics Completes FDA Meeting on (Z)-Endoxifen Strategy - TradingView

Dec 04, 2025

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum - PR Newswire

Dec 04, 2025

Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Rating of "Hold" by Analysts - MarketBeat

Dec 04, 2025

Is Atossa Therapeutics Inc. (YAG2) stock considered safe havenJuly 2025 Intraday Action & AI Driven Stock Movement Reports - Newser

Dec 04, 2025

Is Atossa Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Big Picture & Step-by-Step Swing Trade Plans - Newser

Dec 04, 2025

Is Atossa Therapeutics Inc. (YAG2) stock good for long term investingWeekly Investment Summary & Low Risk Entry Point Guides - Newser

Dec 04, 2025

Dec 03, 2025

Adversity is less terrifying than hope: Atossa Therapeutics Inc (ATOS) - Setenews

Dec 03, 2025

Will Atossa Therapeutics Inc. stock beat EPS estimates2025 Key Highlights & High Return Stock Watch Alerts - Newser

Dec 03, 2025

How Atossa Therapeutics Inc. (YAG2) stock performs in easing cyclesWeekly Trend Summary & Risk Controlled Stock Pick Alerts - Newser

Dec 03, 2025

Dec 02, 2025

S P Trends: How buybacks impact ARMOUR Residential REIT Inc stock valuePrice Action & Daily Profit Maximizing Trade Tips - BỘ NỘI VỤ

Dec 02, 2025

Atossa Therapeutics (ATOS) Advances Glioblastoma Research with A - GuruFocus

Dec 02, 2025

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma - PR Newswire

Dec 02, 2025

Can Atossa Therapeutics Inc. (YAG2) stock surprise with quarterly results2025 Momentum Check & Fast Gain Stock Tips - Newser

Dec 02, 2025

Published on: 2025-12-02 04:01:13 - Newser

Dec 02, 2025

Will Atossa Therapeutics Inc. (YAG2) stock hit Wall Street targetsOptions Play & Precise Trade Entry Recommendations - Newser

Dec 02, 2025

Nov 30, 2025

Will Atossa Therapeutics Inc. stock outperform international peersJuly 2025 Levels & Fast Moving Market Watchlists - BỘ NỘI VỤ

Nov 30, 2025

Nov 28, 2025

Is Atossa Therapeutics Inc (ATOS) positioned for future growth? - Setenews

Nov 28, 2025

Nov 27, 2025

Is Atossa Therapeutics Inc. stock a buy before product launches2025 Major Catalysts & Verified Momentum Watchlists - BỘ NỘI VỤ

Nov 27, 2025

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer (PR Newswire) - Aktiellt

Nov 27, 2025

Nov 26, 2025